Biological safety considerations in the production of health care products from recombinant organisms.
Safety considerations in the field of recombinant technology and rDNA production of health care products have been under discussion since the beginning of this technology in 1973 and will certainly go on. However no adverse effects, which could have been attributed to rDNA technology have been observed. On the other hand many life-saving and life-improving drugs have been on the market for many years to the benefit of many patients. New technologies and products thereof often provoke uncertainties about their impact on the environment or society. This article discusses some potential risks in the application of rDNA technology to drugs as well as some benefits for patients, society and environment.
Weibel
E K
EK
Hoffmann-La Roche Ltd, Pharma Research New Technologies, CH-4002 Basel, Switzerland.